Triple inhaler shows promise for COPD sufferers
NCT ID NCT01917331
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tested a new triple-combination inhaler (beclometasone, formoterol, and glycopyrrolate) against a standard two-drug inhaler in 1,368 adults with severe COPD. The study measured changes in lung function and breathlessness over 52 weeks. The goal was to see if the triple therapy provides better symptom control and fewer flare-ups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Beclometasone, formoterol, and glycopyrrolate (triple-combination inhaler)
What this could lead to
If successful, this triple inhaler could offer better lung function and symptom control for people with severe COPD compared to current two-drug inhalers.
What could go wrong
This is a completed phase 3 trial, but results may not apply to all COPD patients. The triple inhaler may cause more side effects (e.g., throat irritation, pneumonia) and may not improve quality of life for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dr Beatrix BALINT
Szeged, 6722, Hungary